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The coxsackie- and adenovirus receptor (CXADR) is a transmembrane protein, which localizes 
at tight junctions (TJ) in epithelial cells. As highlighted by its name, CXADR was initially 
identified as a receptor for type C adenoviruses and group B coxsackieviruses. Subsequently, 
CXADR has been shown to mediate cell-cell adhesion, immune cell activation and cellular 
signaling. Unlike other TJ components, CXADR is vital for the early stages of development. 
Deregulation of CXADR is frequently observed in pathological conditions including cancer 
and chronic inflammation. However, mechanistic insight into the role of CXADR in 
pathophysiology has been lacking. The overall aim of this thesis was therefore to study the role 
of CXADR in cancer progression and inflammatory diseases.  
In Paper I, we show that CXADR regulates the capacity of breast cancer cells to undergo 
epithelial-mesenchymal transition (EMT) in response to the cytokine TGF-β1. The mechanism 
was traced to a previously unidentified role of CXADR in acting as a negative regulator of the 
AKT signaling pathway by forming a signalosome with, PTEN and PHLPP2. Through loss- 
and gain-of-function experiments we showed that by regulating the stability of the signalosome 
at tight junction, CXADR controls AKT activity and epithelial-mesenchymal plasticity in 
breast cancer cells. Moreover, we found that loss of CXADR correlated with loss of PTEN and 
PHLPP2, and poor prognosis in luminal A breast cancer.  
In Paper II, we found that CXADR expression is significantly induced during the formation of 
atherosclerotic plaques in arterial walls. Macrophages were identified as a previously unknown 
cellular source of CXADR in both murine and human atherosclerotic plaques. A combination 
of gene expression profiling, mass spectrometric analysis and in vitro studies using human 
monocytes (THP1 cells), revealed that the induction of CXADR expression is linked to 
monocyte-macrophage differentiation and further polarization into M1 subtype, and foam cells. 
Intriguingly, we also found a significant correlation between CXADR and receptors for other 
viruses, associated with atherosclerosis in human plaques.  
In Paper III, inspired by the results from Paper I, we show that CXADR also regulates the 
metabolic arm downstream of AKT. We found that CXADR controls glucose uptake in various 
types of cells by regulating the expression and localization of the glucose transporter GLUT-1. 
Further studies revealed that CXADR expression is upregulated in heart and liver tissues in a 
mouse model of type 2 diabetes (T2D). In line with this, we found that CXADR expression is 
induced by IL-6, an inflammatory cytokine which is known to play a role in T2D.  
In conclusion, the results presented in this thesis provide a novel and mechanistic insight into 
the role of CXADR as a pathogenic factor in breast cancer progression and suggest that 
CXADR contributes to the progression of chronic inflammatory diseases including 
atherosclerosis and T2D. This may offer new possibilities for using CXADR as a target to 
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1 REVIEW OF THE RESEARCH FIELD 
1.1 CELL PLASTICITY 
Cell plasticity is the ability of a cell to adapt to a new environment by changing its phenotype 
and identity through molecular reprogramming. While the importance of cell plasticity is well 
known for the development of an embryo, tissue regeneration and wound healing, there is 
increasing interest of cell plasticity in stem cell biology, regenerative medicine and cancer (1). 
The reversible or irreversible nature of the plasticity process appears to be context-dependent. 
There are different forms which empower cells to adopt plasticity along a phenotypic spectrum. 
First mechanism is de-differentiation, in which a well differentiated cell reverts into a less 
specialized cell type while keeps the same cell linage; this can be a stem cell or a progenitor 
cell. On the contrary, trans-differentiation is the procedure in which conversion of a committed 
cell to another differentiated cell type, possibly from a distinct cell linage occurs. The third 
mechanism which results in a switch in lineage commitment in a stem or progenitor cell into 
another related pool of cells, is called trans-determination and forms the basis of metaplasia at 
the level of an entire tissue. Another form of cellular plasticity is the epithelial–mesenchymal 
transition (EMT), in which polarized epithelial cells take on mesenchymal characteristics and 
gain migratory and invasive properties (1-4).  
1.1.1  Physiological Role of Cell Plasticity  
Cell plasticity is crucial during embryogenesis and occurs mostly unidirectional from 
transformation of a totipotent zygote to a pluripotent stem cell and eventually to an unipotent 
differentiated cell state (2). The dynamic interplay between EMT and the reverse mechanism 
of mesenchymal to epithelial transition (MET), is necessary for the generation of mesenchymal 
and epithelium tissues during development (5, 6).  
Formation of mesoderm and endoderm during gastrulation is a well-established example of 
EMT. During this process epiblasts lose their epithelial features -i.e. loss of apical-basal 
polarity and cell-cell junctions- and migrate through the primitive streak to form the basis of 
three embryonic germ layers. It is also shown that cell plasticity in the form of EMT is crucial 
for detachment, migration and final fate of neural crest cells and its differentiated descendant 
cells in heart, thymus, and melanocytes in the skin. The importance of epithelial mesenchymal 
plasticity is also known in the organogenesis of the liver and kidney among other tissues (2, 7, 
8). EMT is coordinated at transcriptional, post-translational and epigenetic levels which will 
be discussed in detail under section 1.2. 
During adulthood, EMT and cell plasticity are rare incidents, but they can be reactivated under 
physiological and pathophysiological conditions such as tissue injury, inflammation, wound 
healing, and cancer (Fig. 1). A well-known demonstration of cell plasticity in adult tissue, is 
found in stem cells of the intestinal crypt. LGR5+ cells in the crypt are the result of either 
dedifferentiation of a common progenitor cell or a more differentiated secretory cell which are 
located in the higher position in the crypt (9, 10).  
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Wound healing is a complex and dynamic cellular process which initiates upon primary 
inflammation due to tissue injury. EMT and its reversed form MET, orchestrate de- and re-
epithelialization during wound healing. The signals from the inflammation site result in 
activation of EMT transcription factors that cause alteration in gene expression depending on 
the microenvironment context and the injured tissue. The process starts by epithelial cells 
surrounding the wound losing their epithelial traits such as cell-cell junctions, polarity and 
loosen up their interaction to the extracellular matrix (ECM); all these events result in 
transformation of cells into a mesenchymal and migratory state. Later, cells which have 
undergone partial EMT, revert to a more epithelial phenotype regulated by signals transduction 
from the new microenvironment, and start to proliferate and differentiate into keratinocytes 
within the injured site (11, 12). 
 
Figure 1. Cell plasticity plays a vital role in physiological process including embryonic development and 
wound healing. It also has pathological role in diseases associated with inflammation, including cancer. 
Epithelial–mesenchymal plasticity is the main form of cell plasticity during cancer progression and is 
believed to associate with therapy resistance, immune evasion and stemness. (Modified from (3))                                         
 
1.1.2  Cell plasticity in Chronic inflammatory Diseases 
Among immune cells, macrophages are divers set of cells playing crucial role at the first-line 
of defense against infection and inflammatory response. Plasticity is a signature of 
macrophages and provide them with a unique adaptability to polarize differently depending 
on the context and the microenvironment. Similar to epithelial cells undergoing EMT, 
macrophages may show a continuous spectrum of phenotypes in response to intrinsic and 
extrinsic stimuli. However, they are generally classified into two, yet heterogeneous but 
distinct subsets of either M1- (pro-inflammatory) or M2- (anti-inflammatory) polarized 
macrophages (13).  
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Within the inflammatory microenvironment, a complex network of signals is believed to 
govern macrophage plasticity, polarization, and function. In turn, different subsets of 
macrophages also are considered as potent drivers of inflammation, by secreting a wide range 
of cytokines, under pathological conditions such as cancer, atherosclerosis, and T2D.   
Macrophages can be regarded as the most prevalent tumor infiltrating immune cells (14). 
Depending on the acquired phenotype, macrophages can play distinct and contrary roles at 
different stages of carcinogenesis. During early stages of tumor progression, M1-like cells 
act as protective killer cells and control tumor cell proliferation together with T cells. At later 
stages of cancer progression, M2 like macrophages secrete factors that can promote tumor 
growth and invasion (15). The notion that local inflammation is a hallmark of cancer, tumor-
associated macrophages (TAMs) may be considered as the key inflammatory mediators of 
linking cancer progression to chronic inflammation. TAMs also contribute to angiogenesis, 
deconstruction of ECM and promoting of cancer cell invasion and migration in different type 
of carcinomas including breast, prostate and lung cancers (16).  
Obesity is considered as a low grade, chronic inflammatory disease that is associated with 
increased risk of developing cancer, cardiovascular disease and T2D (17). As mentioned 
earlier macrophages have plastic nature and the shift between tow subtypes has been reported 
in several studies. For example, a switch from M2- to M1-like subtype in obese adipose 
tissue, results in production of proinflammatory cytokine such as interleukin-6 (IL-6), 
Intelukine-1β (IL-1β) and tumor necrosis factor- α (TNF-α) which eventually can lead to 
insulin resistance (18). In line with this, it is known that increased plasma levels of IL-6 is 
associated with increased body mass (BMI) and obesity while a reduction in BMI leads to 
decreased IL-6 levels (19). Moreover, inhibition of IL-6 has been shown to have a beneficial 
effect on adipose tissue inflammation and insulin resistance in mouse model (20); however, 
the precise cellular mechanism is not known well.  
Atherosclerosis is a chronic inflammatory disease driven by impaired lipid metabolism and 
compromised immune response, which leads to plaque formation and restricted blood flow. 
During gradual progression of the disease, recruitment of monocyte and their differentiation 
into macrophages, occur as a result of sustained vascular walls inflammation, accumulated 
LDL, and its oxidized derivatives (21). Both M1 and M2 macrophages are found within 
atherosclerotic plaques. Indeed, has been shown that while foam cells, originate from M1 
macrophages, found abundantly in the developed lipid core, M2 macrophages are present in 
the adventitia of normal arteries and contribute to plaque regression (22).  
1.1.3  Cell Plasticity in Cancer  
Cell plasticity is essential for normal homeostasis however, when excessive and aberrant can 
contribute to cancer. Signaling pathways that are involved in development, tissue 
regeneration or wound healing can be hijacked by cancer cells and promote tumor 
progression and chemoresistance (1, 3). In line with this, tumor considered as a wound that 
never heals (23). Heterogeneity and phenotypic adaptation are characteristics of cancer cells 
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in the mass of a tumor. EMT is considered as a central mechanism for cancer cell plasticity. 
A majority of adenocarcinomas are believed to originate from chronically damaged and 
inflamed tissues. Chronic inflammation is therefore considered a hallmark of cancer, and 
plays an important role during tumor initiation, progression, and metastasis (15). Infiltrating 
immune cells, such as macrophages and lymphocytes, fuel the tumor microenvironment 
(TME) by secreting various inflammatory cytokines and growth factors that contribute to 
tumor angiogenesis, fibrosis, and release of EMT signaling factors such as transforming 
growth factor β1 (TGF-β1), epidermal growth factor (EGF) and WNT ligands. TGF-β, which 
is the most potent inducer of EMT, signals through SMAD transcription factors that after 
translocation to the nucleus, interact with DNA-binding cofactors and induce expression of 
core EMT transcription factors, such as SNAIL, TWIST and zinc finger E-box-binding 
homeobox (ZEB) (24).  
       
Figure 2. Epithelial–mesenchymal plasticity. Tumor cells undergoing EMT lose epithelial characteristics 
and gain mesenchymal properties. However, this process is not binary and partial-EMT cells are defined 
by dual expression of epithelial and mesenchymal genes. Relocalization of the junctional proteins is a 
crucial step during pEMT (Modified from (25)).  
The importance of EMT in metastasis has been shown in different cancers including breast, 
colon, and liver carcinoma. During cancer dissemination epithelial cells lose their contact 
with neighboring cells. As a result of developing mesenchymal features, cells become 
migratory and invasive. These EMT like cells can intravasate into the lymphatic or blood 
system, reach to the secondary site and form a new distance colony (6, 26). It is still matter 
of debate whether tumor cells need to revert back to an epithelial state through MET in order 
to establish growth at secondary sites (27, 28). 
It is important to note that EMT should not be regarded as a binary phenomenon, but it is 
rather a plastic process. Depends on microenvironment, metastatic tumor cells may display 
a spectrum of both epithelial and mesenchymal features (Fig.2). The concept of intermediate 
states and plasticity evolved the definition of EMT and proposed a new term in the cancer 
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field: partial EMT (pEMT). pEMT, intermediate or incomplete EMT is referring to a state(s), 
in which cells simultaneously express epithelial and mesenchymal genes (6, 25, 26). 
Interestingly, it has been shown that cancer cells expressing mesenchymal genes while still 
retaining some epithelial features, are highly efficient in metastasizing (29, 30).  
Taken together our current knowledge, highlights the important role of epithelial-mesenchymal 
plasticity in different stage of metastasis; at the primary site, mesenchymal phenotypes 
stimulate migratory and invasive behavior, while epithelial characteristics promote outgrowth 
and the formation of secondary tumors at metastatic sites (31). 
1.2  CANCER PROGRESSION AND METASTASIS  
Metastasis is the major cause of mortality in humans with cancer. Unfortunately, there is no 
efficient way to combat metastasis mostly due to two major reasons: first, because of the 
limited understanding of the precise molecular mechanisms behind metastatic spread of 
tumor cells and second, the majority of existing therapeutic approaches have been evolved 
against tumor cell proliferation rather than tumor cell migration and invasion. Despite 
advanced cancer therapies including surgery combined with radiotherapy and/or 
chemotherapy, metastatic cancer cells are difficult to target and are frequently chemo-
resistant (32). It is also important to understand that clinically detectable metastases is the 
end of a complex, multistep process, which was initiated by dissemination of cancer cells to 
the circulation long before diagnosis (Fig. 3) (33). Malignant tumor cells invading and 
migrating into the neighbor tissue may spread further by intravasating into blood or lymphatic 
vessels, and eventually infiltrating at distant sites (34).  
1.2.1  Epithelial-Mesenchymal Transition (EMT) 
The tumor mass is not only referred to a heterogeneous population of cancer cells, but it also 
consists of the tumor microenvironment including cancer stem cells (CSCs), cancer-
associated fibroblasts (CAFs), and different types of immune cells, such as TAMs, dendritic 
cells (DCs), T and B cells (35). These cells produce and secrete proteases, growth factors and 
cytokines, which may trigger re-activation of developmental processes, such as angiogenesis, 
lymphangiogenesis, and EMT (15, 36). 
Accumulating data from animal models of breast and lung carcinoma suggest that EMT 
promotes metastasis by providing cancer cells with migratory, invasive and stemness 
properties, as well as resistance to chemotherapy (37-39). Clinical studies have revealed 
EMT-like cells among malignant cells in the invasive front of numbers of tumor types such 
as breast, colon and lung cancer. Moreover, in vitro studies bring new insight into the 
mechanism underling EMT (40, 41).  
Manifested EMT is the result of a series of events including loss of baso-apical polarization 
due to loss of cell junction components –e.g. E-cadherin and the Coxsackie- and Adenovirus 
Receptor (CXADR), single cell formation and decrease in cell–cell adhesion forces, gain of 
 
6 
motility and invasive properties that empower cells to migrate through the extracellular 
matrix and disseminate further (42, 43).  
 
 
Figure 3. The metastasis processes. Metastasis is series of events that starts with invasion and  migration 
of cancer cells from the primary tumor and ends in the formation of metastasis in distant organs 
(Modified from (33)). 
 
1.2.2  EMT as a link between Cancer and Inflammation 
It is shown that chronic inflammation increases the risk of tumor progression in different 
types of carcinomas such as breast and skin cancer (16). In line with this, long-term intake of 
non-steroidal anti-inflammatory drugs (NSAIDs) is reported to be associated with a 
decreased risk of developing metastatic disease in gastric, biliary and breast cancer (44, 45).  
As chronic and local inflammation considered as a hallmark of cancer, infiltrated immune 
cells within tumor microenvironment, secrete wide array of inflammatory cytokines such as  
TGF-β1, TNFα and interleukins (23). Theses chemokine and growth factors can promote 
recruitment of additional innate immune cells, fuel the so‐called ‘’cytokine storm’’ and 
effectively contribute to induction of EMT involving TGF-β and other cytokines (45).  
Similar to TGF-β1, IL-6, a cytokine abundantly expressed during inflammatory condition 
and in cancer tissues, is capable of inducing EMT in breast cancer and other tumor cells (46). 
IL-6 is mostly considered as a pro-inflammatory cytokine, which contributes to cancer 
progression and relapse; however, recent studies propose homeostatic and anti-inflammatory 
effects of IL-6 depending on the context and source of the cytokine production (47, 48). 
Moreover, the cellular response to IL-6 can vary depending on the chronic or acute exposure 
to this cytokine (47). For example concerning the importance of IL-6 in metabolism, 
particularly glucose uptake in response to insulin, acute bioavailability of IL-6 after physical 
exercise is beneficial for whole body insulin response and lead to increased glucose uptake 
in muscle cells, whereas its chronic bioavailability may affect metabolism adversely and can 




1.2.3  TGF-β-induced EMT Signaling Pathways 
Several signaling pathways, such as EGF, Wnt/beta-catenin, TGF-β as well as 
microenvironment stress (e.g. hypoxia, oxidative and metabolic stress) can induce EMT (50). 
Among those, TGF-β1 is considered as a potent inducer of EMT, which is frequently secreted 
by stroma and immune cells in the tumor microenvironment (51).  
TGF-β is an evolutionarily conserved pleiotropic factor belongs to the TGFβ-superfamily, 
consist of more than 33 proteins, that regulates different biological processes in the cell such 
as cell cycle, differentiation, adhesion, apoptosis, and migration. While TGF-β plays a role 
in tissue growth and morphogenesis during embryonic development, it also important to 
maintain tissue homeostasis through its growth inhibitory effects (52). Perturbations in TGF-
β signaling contribute to inflammatory diseases and tumor progression (53). 
The same paradoxical concept of action of TGF-β can be found during different stage of 
tumorigenesis; TGF-β serves as a potent tumor suppressor at early stages but promotes EMT 
and invasion at later stages of tumor progression (54). An interesting example of the dual 
role of TGF-β was shown in metastatic mammary tumors expressing constitutive active TGF-
β receptor I (TGF-βR1) that inhibited the growth of neu-driven mammary tumor in mice on 
one hand, but also simultaneously facilitated extravasation of tumor cells and formation of 
metastasis to lung parenchyma, in the same animal (55).  
1.2.4  Smad-dependent TGF-β Induction of EMT 
The dual role of TGF-β involves different levels of signaling and transcriptional regulation. 
TGF-β signaling is initiated upon interaction between TGF-β1 with the serine/threonine 
kinase TGF-β receptor II (TGF-β1RII), which in turn phosphorylates TGF-β1RI and 
subsequently forms a heteromeric ligand-receptor complex in the cytoplasm (56). It has been 
shown that occludin, a tight junction protein, contributes to recruitment of TGF-β1RI to the 
membrane (57). Activated kinase receptor-complex regulates signaling cascade through 
phosphorylation of the transcription factors and effectors Smad-2 and Smad-3, at their C-
terminal serine residues. Later these elements form a trimeric complex with the cofactor 
Smad4. Smad-complexes can regulate expression of EMT associated core transcription 
factors like SNAIL1, ZEB1/2, TWIST, CCAAT/enhancer-binding protein (C/EBPβ) and β-
catenin. Formation of the EMT promoting Smad complexes (EPSC) leads to induction of 
mesenchymal genes and simultaneously repression of epithelial genes expression (58-60).  
1.2.5  Smad-independent TGF-β Induction of EMT 
While the Smad pathway is regarded as the canonical TGF-β signaling pathway, non-Smad 
pathways including ERK-P38 MAPK, Rho-like GTPase and phosphatidylinositol 3-kinase/ 
protein kinase-B (PI3K/AKT) pathways are playing important roles during the TGF-β 




regulated through different cellular processes including glycogenesis, glycogenolysis, 
glycolysis and gluconeogenesis.  
Under aerobic conditions normal cells relay on mitochondrial oxidative phosphorylation 
(OXPHOS), which starts in the cytoplasm by production of pyruvate from glucose and then 
proceeds in the mitochondria to produce energy-storing molecules in form of ATP. However, 
under anaerobic conditions or hypoxia, normal cells shift their metabolism toward glycolysis. 
Glycolysis is a procedure regulated by ten enzymatic reactions, initiated by processing 
glucose to pyruvate and ultimately to lactate merely in the cytoplasm. Final products of 
glycolysis are ATP, NADPH and pyruvate in aerobic settings and lactate in anaerobic 
conditions which eventually can enter the Krebs cycle and be used as precursor for other 
cellular reactions. 
Altered energy metabolism is a hallmark of cancer cells (15). Despite a very low energy 
production efficiency of glycolysis compare to OXPHOS (2 vs. 36), most cancer cells use 
glycolysis even in the presence of sufficient oxygen levels. To maintain the elevated rate of 
glucose consumption for aerobic glycolysis, glucose uptake is accelerated up to around 30-
fold in some cancer cells compare to the normal cells. The high rate of glycolysis in cancer 
cells provides substantial levels of intermediates that are essential for synthesis of 
macromolecules and fast growth of tumor cells. Aerobic glycolysis was initially discovered 
by Otto Warburg in 1926 and thus later termed the ‘’Warburg effect’’ in cancer cells (67).  
1.3.1  GLUT-1 in Health and Disease 
To make glucose available for the cells to use, it needs to be transported across the cell 
membrane into the cytoplasm. There are two main glucose transporters (GLUTs) control 
uptake of glucose into the cells: sodium dependent (SGLTs) and facilitative GLUTs. Among 
the later, GLUT-1 is the ubiquitous glucose transporter, which is present in most cell types 
and tissues and facilitates basal uptake of glucose (68).  
It is known that GLUT-1 is widely expressed in endothelial cells that form blood–tissue 
barriers. Moreover, GLUT-1 is highly expressed during different stage of embryogenesis. In 
line with this it is shown that maternal diabetes with hyperglycemia, leading to GLUT-1 
reduction and induction of apoptosis, is lethal and causes the death of murine embryo (69). 
However, GLUT-1 plays less important role in uptake of glucose in insulin-sensitive tissues, 
such as adipose tissue and muscle, where it is present in association with GLUT-4 (70). 
Among other factors excessive hyperglycemia is considered a high-risk condition that 
predisposes individuals to development of T2D. Impaired clearance of glucose from the 
blood, is a hallmark of insulin resistance in T2D. This is due to weakened insulin-stimulated 
glucose flux into muscle and adipocytes and has been linked to altered expression and 
localization of GLUT-4 (71). In the context of diabetes mellitus, it has been shown that 
GLUT-1 overexpression play important roles in the pathophysiology of diabetic-induced 
kidney lesions and nephropathy (72). 
 
10 
Increased uptake and utilization of glucose have been reported in majority of human tumors. 
This was observed with a help of radiolabeled analog of glucose (18F-fluorodeoxyglucose, 
FDG) as a reporter by using positron emission tomography (PET) (73). Additionally, the 
correlation between enhanced glucose uptake, which is mostly mediated by overexpression 
of GlUT-1, with tumor invasion and metastasis to distant sites is documented by FDG-PET 
imaging and immunohistochemistry (74). Elevated expression levels of GLUT-1 is 
associated with poor survival in a variety of human tumors including lung and breast cancers 
(75, 76). In light of these observations, it is believed that a clearer understanding of glucose 
metabolism could provide better therapeutic approaches for cancer and T2D. 
1.3.2  AKT Regulating Glucose Metabolism 
The AKT signaling pathway plays an important role in regulating cellular metabolism and is 
often hyper-activated in tumors. AKT regulates glucose uptake and metabolism both at the 
transcriptional and protein levels. It has been shown that AKT modulates GLUT-1 mRNA 
translation indirectly through mTORC1 and hypoxia-inducible factor-1 (HIF-1α) (77). 
Moreover, one of the major effects of AKT is to promote trafficking of glucose transporters 
(GLUT-1/4) to the plasma membrane and increase glucose flux in favor of glycolysis, which 
is seen in cancer cells with an enhanced glycolysis rate (78).  
Notably, malignant cells with hyperactive AKT show an elevated glucose uptake without an 
increase in total oxygen consumption, suggesting that activation of AKT signaling may 
contribute to stimulation of aerobic glycolysis in cancer cells (79). Besides the capacity of 
AKT to regulate glucose transporters, this serine-threonine kinase can also activate 
hexokinase 2 and phosphofructokinase 1, important glycolytic enzymes, and hence increase 
the rate of glycolysis (80).   
However, hyperactivation of AKT signaling has been reported in many types of human 
cancer, impaired AKT signaling and reduced cellular uptake of glucose are considered as 
hallmarks of T2D (81). 
1.3.3  Regulation of AKT Signaling  
Upon binding of a growth factor to a tyrosine kinase receptor, such as insulin receptors (IRs) 
and/or IL-6R/JAK-STAT3, PI3K is phosphorylated and convert phosphatidylinositol (3, 4)-
bisphosphate (PIP2) lipids to phosphatidylinositol (3,4,5)-trisphosphate (PIP3). PIP3 acts as 
a secondary messenger, which recruits AKT to the plasma membrane and facilitates its 
phosphorylation at threonine 308 (T308) and serine 473 (S473) residues in association with 
different protein kinases such as PI3-K-dependent kinase (PDK1/2) and mTORC2.  
The PI3K/AKT pathway is negatively regulated by different cellular phosphatases including 
phosphatase and tensin homolog (PTEN), and the PH-domain leucine-rich-repeat-containing 
protein phosphatases (PHLPP1/2) (Fig. 5). PTEN prevents AKT activation by converting 
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PIP3 to PIP2, thus by counteracting PI3K (82). PHLPP2 inactivates AKT (AKT1/3) by 
dephosphorylating it directly on serine and threonine sites (83).  
It is well known that PTEN, and more recently PHLPP2, function as a tumor suppressor in 
mammalian cells. PTEN is among the most inactivated phosphatases in different types of 
cancer such as breast, glioblastoma and prostate cancer (84, 85).  
 
 
Figure 5. Schematic illustration of the AKT signaling pathway. PI3k/AKT has a central role a wide range 
of cellular signaling pathways including survival, proliferation, glucose metabolism and EMT. While 
AKT is phosphorylated and activated by PIP3, PTEN and PHLPP2 negatively regulate its activity by 
either preventing phosphorylation or dephosphorylating AKT. ( Modified from  (86)) 
In the case of sporadic breast tumors, less than 5% PTEN mutations have been reported, 
although loss of PTEN immunoreactivity is observed in about 40% of the same cohort, 
suggesting an alternative and post-translational inactivation of PTEN instead of merely 
mutation or gene deletion (87). In line with this, it has been shown that phosphorylation can 
regulate stability and activity of PTEN (88).  
PTEN contains a functional PDZ domain-binding motif at its C-terminus. Phosphorylation 
of PTEN at the C-terminus, causes a conformation change termed as ‘’closed’’ and make 
PTEN less able to engage in PDZ domain-dependent interactions with other PDZ-containing 
proteins such as members of the family of membrane-associated guanylate kinase inverted 
(MAGI-1/3). Binding of PTEN to MAGI-proteins is believed to facilitate translocation of 
PTEN to the plasma membrane, specifically to the cell-cell junctions, where is the focal point 




in turn can induce an inhibitory signaling cascade on AKT pathway (90). Therefore, TJs can 
transmit external signal and act as hubs for intracellular signaling networks controlling 
epithelial cell fate and function.  
Considering the fact that more than 80% of human cancers originate from epithelial cells 
(carcinoma), it is not surprising that TJs play role in tumor progression and EMT (97). As 
EMT is a plastic and multi-step procedure, TJs can influence EMT and metastasis at several 
levels. Within a tumor, TJs preserve cell adhesion to prevent cancer cell dissemination, 
therefore they can be referred as the cellular “gatekeepers” to protect cells from undergoing 
EMT. Moreover, TJs maintain epithelial cell polarization in association with, an 
evolutionarily conserved signaling pathway, atypical protein kinase C (aPKC) (98).  
Recently it was shown that components of TJs, such as occludin and ZO-1, regulate epithelial 
proliferation and differentiation (99). Interestingly, occludin has been shown to mediate 
recruitment of TGF-β1R1 to the membrane which means that the TGFβ signaling cascade, 
leading to EMT, starts at TJs (57). Moreover, TGF-β-PKCα-PTEN cascade is shown to play 
important role in metastasis and proliferation of pancreatic cancer (100). Although 
deregulation of TJ is considered as a hallmark of EMT, the precise signaling mechanisms 
connecting TJ to the induction of EMT are not well characterized. 
1.4.1  CXADR – a TJ Protein with an Ambiguous Function in Epithelial Cells 
CXADR is a 46-kDa transmembrane tight junction protein belongs to the immunoglobulin 
superfamily (IgSF). CXADR is a unique TJ protein that its genetic deletion leads to mouse 
embryonic lethality between E11.5-E13.5, due to impaired cardiomyocyte development and 
heart failure (101). CXADR-deficiency during development results in subcutaneous edema, 
which is associated with structurally abnormal and dilated lymphatic vessels (102). 
Moreover, conditional ablation of the CXADR gene (CXADR) in adult mice results in dilation 
of the intestinal tract and acinar-to ductal metaplasia of the exocrine pancreas (103).  
As the name suggests, CXADR was originally discovered as a cellular receptor for group B 
coxsackieviruses (CVB) and type C adenoviruses (104). Thereafter CXADR was shown to 
be a component of epithelial tight junctions, which can interact with CXADR molecules on 
adjacent cells. The CXADR gene is located on chromosome 21q11.1 and is composed of 8 
exons (105). CXADR produces different splice variants including three soluble isoforms and 
two transmembrane isoforms named human hCXADR1 (TVV) and hCXADR2 (SIV), which 
differ slightly in their intracellular domain and their expression in different tissues (106, 107). 
Membrane-bound isoform of CXADR contain two Ig-like domains in its extracellular 
domain, which are responsible for homo- or hetero-dimerization to the extracellular matrix 
proteins (e.g. fibronectin) and other members of IgSF family such as JAM-L or JAM-C (108, 
109). It has been shown that the CXADR and JAM-L interaction plays a role in immunity, 
inflammation, and tissue homeostasis. Upon binding of CXADR to JAM-L on the surface of 
γδ T-cells, PI3K is recruited and activated at the tight junction. This can subsequently lead to 
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increased proliferation and cytokine production of T-cell (110, 111). Moreover, It has been 
found that binding of CXADR on epithelial cells to JAM-L on neutrophils is important during 
neutrophil transmigration across TJs (112).  
The intracellular domain of CXADR carries different motifs namely a class-I PDZ domain 
located at the extremity of the C-terminus (SIV or TVV). The PDZ motif is conserved 
between spices of human and mouse which enable CXADR protein to bind to the adaptor 
proteins contain PDZ domain such as ZO-1, multi-PDZ domain protein-1 (MUPP-1), E3 
ubiquitin-protein ligase (LNX) and MAGI-1 (113, 114). This makes CXADR an interesting 
candidate to be involved in different intracellular protein complex and signaling networks, 
particularly in epithelial cells. 
1.4.2  CXADR in Development, Inflammation and Cancer 
CXADR shows developmental and tissue-specific expression. While it is highly expressed 
during murine embryogenesis particularly in brain, skeletal and heart muscles, CXADR 
expression is lowered significantly in adult mice tissues (115, 116). Despite developmental-
dependent expression of CXADR in brain and heart muscle, it is found to be expressed 
constantly high in polarized epithelial cells of different organs such as gastrointestinal tract, 
male reproductive system, respiratory tract and mammary gland in adult mice and humans 
(107). CXADR is also present in the liver, lymphatic system, skeletal muscle, and myocardial 
cells (114, 117). However it is known that CXADR is not expressed in the endothelium of 
vessels in intact tissue, its expression has been detected in CD31+ (endothelial marker) cells 
in damaged areas of the heart (118). 
The restricted expression pattern of CXADR in adult tissues suggests an exclusive role during 
development and tissue homeostasis. In adult heart tissue, CXADR is exclusively expressed 
in intercalated disks and plays a role in cardiac remodeling and electrical conductance 
between the atrium and ventricle (107). It has been shown that CXADR expression is 
deregulated under different pathological conditions such as cancer, chronic inflammation, 
and cardiac disease (119).  
As mentioned earlier unlike other members of TJs, knockout of CXADR in mice is lethal 
between 11.5 and 13.5 embryonic days due to impaired heart and the lymphatic system 
development. Moreover, it was shown that cardiomyocytes had enlarged mitochondria and 
glycogen storage enriched in these cells (101, 102, 120). Several knockdown mouse models 
confirmed the unique role of CXADR for embryonic heart development and function (120-
123). In one study it is shown that CXADR-deficient mice demonstrated over-proliferative 
and disorganized cardiomyocytes with poor differentiation causing hyperplasia of the left 
ventricle and death at embryonic day 12.5 (124).  
It is worthwhile to note that, conditional inactivation of CXADR gene in adult mice results in 
multiple phenotypes including dilatation of the intestinal tract and atrophy of the exocrine 




effect in the pathogenesis of inflammatory bowel disease (IBD) by preventing TNF-α- 
induced inflammation and save the epithelial integrity in human colon cells (129). 
CXADR -as a virus receptor- contributes to induction of inflammation upon virus infection 
through activation of the MAPK, JNK, and NF-κB pathways (130). Interestingly it has been 
shown that CXADR expression itself -independent of viral infection- can also induce 
inflammation in the myocarditis animal model. CXADR-cardiac inflammation was reported 
to be as a result of CXADR-induced stress-activated MAPK signaling pathway followed by 
infiltration of mononuclear cell (mostly NK cells and macrophages) and induction of 
inflammatory cytokine such as IL-1β and IL-6 in the heart tissue of transgenic 
mCAR+/αMtTA+  mouse model (131). 
 With the establishment of gene therapy, particularly with oncolytic adenoviruses (e.g. Ad5) 
for battling cancer cells, and the fact that CXADR has high binding affinity to adenoviruses, 
multitude of cancer cells have been examined for CXADR expression levels (132). Impaired 
expression and localization of CXADR is reported in many cancer cells as well as in a number 
of different human tumors, particularly in those displaying loss of differentiation in advanced 
disease stages. Among them are breast cancer, lung cancer, human endometrial 
adenocarcinoma, primary and metastatic colon cancer (108, 133, 134). These studies can 
suggest a tumor-suppressor role for CXADR, which was confirmed in studies demonstrating 
a growth inhibitory effect of CXADR overexpression in CXADR-deficient and tumorigenic 
prostate and bladder cancer cell lines (132, 135). 
Moreover, loss of cell-cell contacts in primary tumor cells enable cancer cell to migrate and 
initiate tumor spread and metastasis. In this context CXADR -as cell-cell adhesion molecule- 
has been reported to be lost or downregulated during metastatic outgrowth in several 
carcinomas (108, 136). With the help of gain- and loss function studies, CXADR has been 
shown to be downregulated early upon induction of EMT with TGF-β1 in a SNAIL-Smad-
dependent fashion (136-139). In line with this, CXADR (together with E-Cadherin), is lost 
at the invasive front of human ductal breast cancer, as well as in the invasive area of the 
xenografts subcutaneously-grown mouse breast carcinomas (137). However, contradictory 
reports showing either decreased, increased, or not significantly changed CXADR level in 
human breast cancer (132, 140-142). 
Taken together these findings highlight the importance of CXADR in organogenesis, 
regulation of inflammation, tissue homeostasis and its function under normal and 
pathological conditions. Considering the fact that CXADR is a multifunctional protein and 
appears to play role in different disease, the novel approaches to regulate CXADR can shed 
light on therapeutic potential of this tight junctional protein in future.    
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2 OVERALL AIMS 
Based on the essential role for CXADR during development, and the documented deregulation 
of CXADR in various cancer and inflammatory diseases, we hypothesized that CXAR might 
play a, yet uncharacterized, role in regulation of signaling mechanisms controlling cellular fate 
and function. The overall aim of this thesis was therefore to study whether CXADR could be 
linked to changes in cell plasticity in breast cancer and chronic inflammatory diseases including 
atherosclerosis and type 2 diabetics.  
2.1  Specific Aims 
The specific aims of the thesis were:  
1. To determine whether CXADR regulates tumor cell plasticity in a model of TGF-β-induced 
EMT (Paper I). 
2. To elucidate whether changes in CXADR expression is associated with atherosclerotic 
plaque formation (Paper II). 
3. To investigate the role of CXADR in regulating cellular uptake of glucose and its possible 













3 RESULTS AND DISCUSSION 
3.1   PAPER I. 
CXADR-Mediated Formation of an AKT Inhibitory Signalosome at Tight 
Junctions Controls Epithelial–Mesenchymal Plasticity in Breast Cancer 
Azadeh Nilchian, J. Johansson, A. Ghalali, S. Asanin, A. Santiago, O. Rosencrantz, K. 
Sollerbrant, T. Vincent, M. Sund, U. Stenius, and Jonas Fuxe 
Rationale 
Loss of CXADR and other TJ proteins is a hallmark and an early event of EMT during 
carcinoma progression. However, it is not known whether CXADR plays a role in regulating 
the EMT process. In this study we explored the role CXADR in regulating TGF-β1-induced 
EMT in breast cancer cells.  
CXADR regulates epithelial–mesenchymal plasticity in mammary tumor and human breast 
cancer cells 
To explore the role of CXADR in EMT, we employed an established model system of TGF-β- 
induced EMT in mouse mammary tumor cells and performed a series of loss- and gain-of-
function experiments. Results from western-blot and immunofluorescence analysis, measuring 
EMT markers (E-cadherin, occludin and vimentin), in EpRas cells treated with TGF-β1 
showed more robust EMT response in cells transfected with CXADR siRNA compared to 
control cells transfected with scrambled siRNA. In contrast, overexpression of CXADR in 
EpXT cells, which display a persistent EMT phenotype due to an autocrine TGF-β1 loop, 
resulted in partial MET, which was evident by increased levels of E-cadherin and occluding, 
and decreased levels of vimentin. Similar results were observed using human MCF-7 and T-
47D breast cancer cells, which are CXADR-negative and CXADR-positive, respectively. 
Moreover, shRNA-mediated CXADR knockdown led to increased capacity of EpRas cells to 
migrate towards a source of TGF-β1 in invasion assays. The opposite results were observed in 
EpXT cells overexpressing CXADR compare to the controls. These results implicated that 
CXADR regulates epithelial–mesenchymal plasticity in breast cancer cells. 
CXADR mediates epithelial–mesenchymal plasticity via the AKT pathway       
While the Smad pathway is the canonical signaling pathway for TGF-β, non-Smad pathways 
including ERK, p38 MAPK, and PI3K/AKT pathways are also important for TGF-β-induced 
EMT. As a next step, we therefore studied which of these signaling pathways that were 
involved in CXADR-mediated regulation of EMT. The results revealed that stable knockdown 
of CXADR in EpRas cells did not affect TGF-β1-induced activation of Smad3, ERK1/2 or p38 
MAP kinase. However, AKT was already activated by knocking down of CXADR (without 
TGF-β1) and further enhanced after treating with TGF-β1. In line with these results, we found 
that the levels of phosphorylated GSK-3β, a downstream substrate of AKT, increased after 
knockdown of CXADR. Moreover, knockdown of CXADR also resulted in enhanced nuclear 
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localization of the core EMT factors SNAIL and TWIST, which are inhibited by GSK-3β. 
Conversely, overexpression of CXADR in EpXT cells resulted in decreased levels of p-GSK-
3β. Altogether, these results suggested that CXADR regulates epithelial–mesenchymal 
plasticity by inhibiting the AKT/GSK-3β-Snail/Twist signaling axis.  
In contrast to cancer cells, most normal epithelial cells are resistant to TGF-β1-induced EMT. 
Moreover, integrity of cell-cell contact in confluent cells, is a potent inhibitor of TGF-β1-
induced EMT and proliferation (contact inhibition) (143). On this notion we highlighted the 
important role of CXADR locating at tight junction, where numbers of stimuli (e.g. TGF-β) 
can trigger AKT hyperactivation, to act as a break on AKT signaling and maintain the epithelial 
fate of cell. 
Direct and indirect control of AKT via CXADR though PHLPP2 and PTEN  
AKT serves as a central player for a wide range of biological processes, thus its activity is 
tightly regulated through phosphorylation. While various growth factors including TGF-β, 
promote activation of AKT, it is negatively regulated by phosphatases including PTEN and 
PHLPP2 (83). Based on our results, we were interested to examine whether CXADR regulated 
AKT via PTEN and PHLPP2. Indeed, knock down experiments in EpRas and T-47D cells 
showed that loss of CXADR resulted in decreased expression of both PTEN and PHLPP2. In 
contrast, overexpression of CXADR in EpXT cells and MCF-7 cells induced expression of 
PTEN and PHLPP2.  
CXADR forms an AKT-inhibitory signalosome at TJ 
CXADR is known to interact with cytoplasmic scaffold proteins containing PDZ domains, such 
as MAGI-1. Similar to CXADR, PTEN and PHLPP2 contain a PDZ binding domain in their 
C-terminus (144, 145). On this note, we hypothesized that PTEN and PHLPP2 might form a 
protein complex with CXADR at TJs. To test this, we performed co-immunoprecipitation 
experiments by pulling down endogenous CXADR, PHLPP2, and PTEN with an antibody 
against MAGI-1 in EpRas cell lysates.  Further analysis revealed that PHLPP2 and CXADR 
interact with the same PDZ domain (#3) of MAGI-1. In addition, we found that CXADR co-
localized with PTEN and PHLPP2 in proximity ligation assays. Moreover, through a set of 
overexpressing experiments in CXADR-negative COS-7 cells, we observed that CXADR 
expression controls function of both phosphatases, evident by further inactivation of AKT in 
cells overexpressing CXADR together with either PHLPP2 or PTEN compare to the control 
cells.  
Hyperactivation of AKT signaling is found in practically all types of human cancer and in some 
cases, correlates with high incidence of PTEN mutations. However, in breast cancer, loss of 
PTEN due to mutagenic events is rare (only 5% of breast tumors). Yet, PTEN 
immunoreactivity is lost at a significantly higher degree (40% of breast tumors), suggesting 
that inactivation of PTEN primarily occurs at the protein level in breast tumors (146). Based 
on this, we think that our identification of CXADR as a regulator of PTEN stability and 
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function as an AKT inhibitor, adds a significant level of new knowledge into the mechanisms 
by which PTEN is lost and AKT hyperactivated in breast cancer.  
Correlation of CXADR expression with loss of PHLPP2 and PTEN, and poor survival in 
luminal A breast cancer 
To study the expression of CXADR in human breast cancer we used the GOBO breast cancer 
database, which is an open access database of 1881 samples of human breast cancer and 51 
human breast cancer cell lines (147). Data analysis showed that CXADR mRNA expression 
negatively correlated with poor survival in luminal A tumors (P=0.002), but not in basal tumors 
or when all tumors were included. To get more insight into whether loss of CXADR correlated 
with loss of the other components of the signalosome, we performed co-staining of CXADR 
and PHLPP2, PTEN, or MAGI-1 in 14 human breast tumors. The data showed heterogenous 
expression of CXADR in the tumors, and a significant correlation between CXADR with 
PTEN, PHLPP2 and MAGI-1 in different tumor regions.  
These observations imply that loss of CXADR might play a significant role for tumor 
progression and survival in luminal A breast cancer because it leads to loss of PTEN and 
PHLPP2 at TJs and thereby hyperactivatino of the AKT signaling pathway (Fig. 8). However, 
in basal tumors, which are poorly differentiated, loss of CXADR expression has less of an 
impact. This indicates that in more differentiated tumors, the existence of CXADR at TJ 
contributes to maintaining epithelial differentiation and preventing induction of EMT, and 
thereby increases the overall survival.  
 
 
Figure 8. CXADR-signalosome mediates TGFβ-induced EMT via regulation of AKT signaling pathway   
 
Metastasis has been considered as the final stage of the cancer which leads to death in more 
than 90% of patients. Yet, most traditional, and novel therapies target tumor cell proliferation 
rather than tumor cell migration and invasion. Our result which identified CXADR as a novel 
regulator of AKT and EMT, may propose possibilities to target CXADR for therapeutic 
intervention in future.  
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3.2   PAPER II.  
Induction of the Coxsackievirus and Adenovirus Receptor in Macrophages 
During the Formation of Atherosclerotic Plaques  
Azadeh Nilchian, E. Plant, M. Parniewska, A. Santiago, A. Rossignoli, J. Skogsberg, U. Hedin, 
L. Matic, and Jonas Fuxe 
Rationale 
Enteroviruses including coxsackievirus B (CVB) have been linked to atherosclerosis, but the 
mechanisms are not clear (148). We hypothesized that the formation of atherosclerotic plaques 
could be linked to changes in the expression of CXADR, which is the main high-affinity 
receptor for CVB and other subtypes of enteroviruses.  
CXADR is induced during plaque formation 
To investigate the possible expression of CXADR in atherosclerotic plaques, large-scale 
microarray analysis was performed on carotid arteries obtained from patients with carotid 
stenosis (n = 127). In comparison to the normal arteries, CXADR expression was significantly 
upregulated in carotid arteries with atherosclerotic plaques (P < 0.001). Additionally, CXADR 
protein levels were also significantly increased in the plaques compared to the adjacent control 
arterial tissue, as determined by proteomic data. To obtain a better insight of CXADR 
expression during plaque formation, we immunostained aortic walls from transgenic Ldlr−/− 
Apob100/100 mice, which is an animal model of atherosclerosis, at 10 weeks (prior to plaque 
formation) and 50 weeks (with an established plaque) of age. In line with the human data, 
CXADR was upregulated in the plaque-invested aortic walls of 50-week old mice but not in 
10-week old ones. Taken together, the data demonstrated that CXADR expression is induced 
during plaque formation in both human carotid arteries and in a mouse model of 
atherosclerosis. 
Identification of plaque resident macrophages as a cellular source of CXADR  
As a next step, we studied which cell type(s) that might express CXADR in plaques. 
Immunohistochemical staining demonstrated that CXADR was co-expressed with CD68 (a 
common marker of macrophages), both in mouse model and human carotid plaques. 
Interestingly, not all macrophages in the human carotid plaque were positive for CXADR 
expression. In line with this, further analysis of human samples revealed a significant 
correlation between CXADR and CD68 mRNA, but not at the protein level. Taken together, 
the data indicated that a subpopulation of CD68-positive cells represent a cellular source of 
CXADR in plaques.  
CXADR expression correlates with M1 and foam cell markers  
The fact that CXADR was highly expressed in a subpopulation of macrophages led us to 
investigate the type of macrophages that are commonly express during plaque formation. 
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Macrophages have an especially plastic nature and can shift their phenotype in response to 
specific microenvironmental stimuli. There are different subpopulations of macrophages in 
plaques which, by compromise, can be classified as M1 (pro-inflammatory) and M2 (anti-
inflammatory) (13). As their names suggest, M1 is more correlated to plaque formation while 
M2 contributes to plaque regression and can be found in adventitia of normal arteries. 
Analyzes of the RNA and proteomic datasets revealed that CXADR expression significantly 
correlated with CD11b and CD11c (markers of M1 and dendritic cells) at both mRNA and 
protein levels. A weaker correlation was found between CXADR and the M2 marker CD163. 
An important part of the atherosclerotic process is that macrophages accumulating in plaques 
take up oxidized low-density lipoproteins (LDL) and thereby turn into foam cells (149). CD36 
a scavenger receptor, shown to mediates cellular uptake of oxidized LDL and contributes to 
foam cell formation. Our results revealed that CXADR correlated strongly with CD36 at 
mRNA and protein levels, suggesting that CXADR is expressed in foam cells within plaques. 
In line with this, we also observed co-staining of CXADR and CD36 carotid plaques by 
immunohistochemistry.  
To elucidate more about the induction of CXADR expression during M1 and M2 polarization, 
we took advantage of a frequently used in vitro model of monocyte-to-macrophage 
differentiation in human THP-1 monocytes. THP-1 cells were first exposed to phorbol-12-
myristate-13-acetate (PMA) to induce M0 macrophages. M0 macrophages were subsequently 
incubated with either IFN-γ and LPS for 24 hours, or with IL-4 and IL-13 for 72 hours, to 
induce polarization into M1 or M2 macrophages, respectively. Western blot analysis and 
immunofluorescent staining showed that CXADR expression was induced upon monocyte-
macrophage differentiation and further during polarization into a M1 phenotype. 
CXADR correlates with receptors for other viruses linked to atherosclerosis 
To learn more about the CXADR expression in plaques, and its association with other 
inflammatory markers, we performed further analysis of the gene expression data. CXADR 
correlated strongly only with a few additional markers including inflammatory cell adhesion 
molecule 1 (ICAM-1), CCR5 and neuropilin-2 (NRP-2). These inflammatory markers have 
been reported to contribute to atherosclerosis initiation, progression and/or mediating 
macrophage recruitment and plaque formation. Interestingly, ICAM-1, CCR5,  and NRP2 have 
also been shown to act as receptors for viruses that have been linked to atherosclerosis including 
rhinoviruses, HIV, and cytomegalovirus respectively (150). In addition to the role of CD36 in 
mediating uptake of oxidized LDL and foam cell formation, it is linked to atherosclerosis 
through its role as a receptor for HCV (151). In line with recent findings from our group 
showing that the transcription factor C/EBP-β is a potent inducer of CXADR expression (152), 
we found a significant correlation between CXADR mRNA with C/EBP-β in human plaques. 
Interestingly, C/EBP-β is also a well-known transcription factor for playing key roles in 
macrophage differentiation and polarization, as well as expression of CCR5 and CD36 (153).  
Since atherosclerosis is considered as a chronic inflammatory disease, it is enticing to speculate 
that CXADR expression in the plaques and infection with common enterovirus eventually can 
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increase vulnerability of macrophages for co-infection with other viruses and triggering of the 
inflammatory response. This in turn could ultimately lead to phagocytosis and development of 
a necrotic core, plaque disruption and myocardial infarction. Future studies are needed to 
elaborate to what extent macrophages in atherosclerotic plaques are prone to infections and co-


























3.3  PAPER III.  
The Coxsackie- and Adenovirus Receptor Regulates Cellular Uptake of Glucose 
and is Linked to Type 2 Diabetes via IL-6 
Nilchian Azadeh, Peterson M, Falkevall A, Eriksson U, Parniewska MM, Fuxe Jonas  
Rationale 
Based on our identification of CXADR as a negative regulator of AKT signaling and the 
induction of EMT in breast cancer cells (paper I), we hypothesized that CXADR might also 
regulate the metabolic arms of the AKT signaling pathway. We therefore set out to analyze 
whether CXADR could regulate glucose uptake in cells.  
CXADR regulates cellular uptake of glucose by regulating GLUT-1 
A series of loss- and gain-of function experiments were performed to elucidate whether 
CXADR levels affected AKT signaling and glucose uptake in various cell types. SiRNA-
mediated knockdown of CXADR in Namru mouse Mammary Gland (NMuMG) epithelial 
cells, which express high levels of CXADR, resulted in increased AKT activity and 
significantly enhanced capacity of cells to take up 2-NBDG (2-(N-(7-Nitrobenz-2-oxa-1,3-
diazol-4-yl)Amino)-2-Deoxyglucose)), a fluorescent derivative of glucose. Conversely, we 
found that overexpression of CXADR resulted in inhibition of AKT and significantly reduced 
uptake of 2-NBDG in mouse MS1 endothelial cells, which express very low levels of CXADR. 
The results prompted us to investigate whether CXADR affected downstream targets of AKT, 
in particular GLUT-1, which is a major glucose transporter in epithelial and endothelial cells. 
In line with the results from glucose uptake studies, we found that GLUT-1 expression 
increased upon knockdown of CXADR in NMuMG cells and conversely, decreased in MS1 
cells after overexpression of CXADR. Immunofluorescence staining confirmed these results 
and furthermore, indicated that CXADR hindered translocation of GLUT-1 from the cytoplasm 
to the plasma membrane. 
Elevation of CXADR expression in T2D mouse model tissues 
Unlike cancer, in which AKT signaling is shown to be overtly active and playing role in the 
glycolytic switch in tumors, inactivation of AKT considered as pathogenic signature of T2D 
development (81). Based on our results showing that CXADR is a negative regulator of glucose 
uptake in cells, we hypothesized that changes in CXADR levels might associate with 
development of T2D. To study this, we employed db/db mouse a spontaneous T2D model. 
Western blot analyses showed significantly increased levels of CXADR in both heart and liver 
tissues from db/db mice compare to control db/+ mice. These results suggested a role for a 
systemic signal as an inducer of CXADR expression during the T2D development. 
IL-6 induces CXADR expression via C/EBP-
Accumulated results suggest that local chronic inflammation (e.g. in obesity), is a strong risk 




4 CONCLUDING REMARKS  
Considering the complexity of human physiology and disease, there is a high demand for 
interdisciplinary studies. Modern medical research cross over classical boundaries and provide 
opportunities to identify and apply new treatment strategies, primarily intended for a specific 
pathological condition, in a different context. Under this light, the results extracted from this 
thesis demonstrates the important role of CXADR, as a multifunctional TJ protein, in bridging 
the seemingly unconnected fields: cancer metastasis, atherosclerosis and T2D. 
The results from our first paper revealed that CXADR regulates EMT via controlling AKT 
activity in breast cancer cells. Deregulation of TJ is a hallmark of EMT, which is known to 
contribute to cancer progression and metastasis. We found that CXADR forms a functional TJ-
based signalosome with two AKT-inhibitory phosphatases PTEN and PHLPP2. Our results 
demonstrated that loss of CXADR sensitizes cells to undergo TGF-induced EMT. Conversely 
restoration of CXADR promotes epithelial differentiation by recruiting and stabilizing the 
AKT-inhibitory signalosome at the TJ. Further investigation revealed that loss of CXADR 
significantly correlated with loss of PTEN and PHLPP2 and poor prognosis in luminal A breast 
cancer. The results from this study indicate that CXADR might be used as a prognostic marker 
and therapeutic target in luminal breast cancer.  
In the second study presented in this thesis, we showed that CXADR expression is induced in 
macrophages during the formation of atherosclerotic plaques. CXADR is a high affinity 
binding receptor for subtypes of enteroviruses that is expressed in the epithelial cells. These 
results, for the first time, identified macrophages as the cellular source of CXADR. However 
not all CD68-positive macrophages were expressing CXADR. This led us to identify foam cells 
and M1 macrophages with a specific correlation with CXADR, accumulating in the 
inflammatory, lipid-rich microenvironment in atherosclerotic plaques. The observed 
significant correlation between CXADR expression and a cluster of receptors for other viruses 
in the plaque, might make the macrophages prone to be infected with several viruses (e.g. 
enteroviruses). This underlies the likelihood of an intense inflammatory trigger leading to 
phagocytosis and cell death which are the risk factors associated with the development of a 
necrotic core, plaque disruption and myocardial infarction. Future studies poised to understand 
that how the biological manipulation of CXADR, affecting the atherosclerotic plaque 
formation and progression. 
The steppingstone to the third paper was the results in paper I, identifying CXADR as novel 
regulator of AKT. Here, we demonstrated that CXADR regulates the capacity of cells to take 
up glucose. Loss of CXADR in epithelial cells resulted in hyperactivation of AKT, 
upregulation of GLUT-1 and increased glucose uptake. On the other hand, overexpression of 
CXADR in endothelial cells inhibited AKT and restricted glucose uptake. Further studies 
showed that CXADR expression was significantly induced in the liver and heart tissues of mice 
developing T2D. Moreover, our results identified IL-6 as an inducer of CXADR expression in 
a C/EBP-dependent manner. Similar to paper I and II, advancement in methods to manipulate 
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CXADR expression in in vivo models are needed to study the importance of CXADR for 
disease induction and progression, however our research shed a light on the potential of 



























5 FUTURE PERSPECTIVES 
The conclusions of the three studies presented in this thesis rise the quest for further 
investigation to obtain better understanding of CXADR causal effect under different 
pathological condition. 
For example, studies using larger cohorts may provide information on whether loss of CXADR 
could be used as a marker to predict malignant progression in luminal breast and/or other types 
of carcinoma. Study on the precise molecular mechanism by which PHLPP2 and PTEN are 
recruited to the CXADR-mediated signalosome at TJs may provide a possible strategy to 
prevent PTEN and PHLPP2 inactivation or malfunction. Since epithelial-mesenchymal 
plasticity is associated with chemoresistance, it would be interesting to elucidate the effect of 
CXADR expression on re-sensitization of cancer cells to commonly used chemotherapeutic 
drugs. 
Considering our observation that CXADR expression was upregulated in a mouse model of 
T2D, it would be interesting to study whether CXADR affects insulin resistance in skeletal 
muscle and adipocyte. In addition to the AKT-dependent GLUT-1 expression mediated by 
CXADR, it should also be valuable to investigate other molecular mechanisms by which 
CXADR regulates GLUT-1, for example a possible molecular competition between CXADR 
and GLUT-1 for binding to the same PDZ domain of the MAGI-1 molecule. 
Based on our results from Paper I and III, it is enticing to speculate that overexpression of 
CXADR in macrophages may inhibit glucose uptake as a consequence of AKT inhibition, and 
instead promote the increase in fatty acid uptake - a mechanism known as Randel cycle (155). 
Randel cycle is cellular process involving the competition between glucose and fatty acids 
cellular flux. 
Furthermore, taking advantage of conditional and tissue specific knockout mouse model can 
provide a new insight on the role of CXADR in induction and/or progression of atherosclerosis 
and T2D in vivo. 
Finally, our attempts to understand more about the contributing role of CXADR in different 
types of disease may open up possibilities to target CXADR, in specific cell types (e.g. 
macrophages and endothelial cells) for AdV-based gene therapy and/or targeting CXADR by 
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